Extensive research has been conducted on the use of immune checkpoint inhibitors, specifically antibodies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1, in the field of cancer immunotherapy. This evidence concerns the gene PDCD1 and cancer.